Blog

U.S. biotechnology company Gilead has conceded its first discounts in Germany on its key hepatitis C drugs Sovaldi and Harvoni, German business weekly WirtschaftsWoche ...

[:content [\D \a \b \r \a \f \e \n \i \b \space \m \e \s \y \l \a \t \e \space \( \T \a \f \i \n \l \a \r \) \space \h \a \s \space \b \e \e \n \space \a \p \p \r \o \v \e \d \space \i \n \space \G \e \r \m \a \n \y \space \s \i \n \c \e \space \A \u \g \u \s \t \space \2 \0 \1 \3 \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t \space \o \f \space \p \a \t \i \e \n \t \s \space \w \i \t \h \  \a \d \v \a \n \c \e \d \space \m \e \l \a \n \o \m \a \. \space \I \n \space \a \n " ..."]]

[:content [\1 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \  \R \a \d \i \u \m \space \R \a \2 \2 \3 \space \d \i \c \h \l \o \r \i \d \e \space \( \X \o \f \i \g \o \) \space \h \a \s \space \b \e \e \n \space \a \p \p \r \o \v \e \d \space \s \i \n \c \e \space \N \o \v \e \m \b \e \r \space \2 \0 \1 \3 \space \f \o \r \space \m \e \n \space \w \i \t \h \space \a \d \v \a \n \c \e \d \space \p \r \o \s \t \a \t \e \space \c \a \n \c \e \r \, \space \i \n " ..."]]

In April 2014 the EU Parliament and Council commissioned the European Medicines Agency (EMA) to establish a publicly accessible database ...

Eisai announced today that its German sales company Eisai GmbH has resubmitted its first-in-class anti-epilepsy drug Fycompa (perampanel) to the German Federal ...

[:content [\2 \space \D \e \c \e \m \b \e \r \space \2 \0 \1 \3 \space \- \space \S \a \x \a \g \l \i \p \t \i \n \space \h \y \d \r \o \c \h \l \o \r \i \d \e \space \( \O \n \g \l \y \z \a \) \space \h \a \s \space \b \e \e \n \space \a \p \p \r \o \v \e \d \space \a \l \s \o \space \a \s \space \m \o \n \o \t \h \e \r \a \p \y \space \i \n \space \G \e \r \m \a \n \y \space \s \i \n \c \e \space \J \u \l \y \space \2 \0 \1 \3 \space \f \o \r \space \c \e \r \t \a \i \n " ..."]]

Internationally health economic evaluations (HEEs) form a legally regulated fixed component in health-care decisions. This applies particularly to the drug ...

1 July 2015 - Novo Nordisk today announced that the company has decided to cease distribution of its once-daily basal insulin ...

Eisai Co., Ltd.  announced today that the German Federal Joint Committee (G-BA) has determined no additional benefit for its in-house ...

[:content [\8 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \  \N \e \a \r \l \y \space \8 \5 \% \space \o \f \space \n \e \w \space \d \r \u \g \s \space \i \n \space \G \e \r \m \a \n \y \space \t \h \a \t \space \w \e \r \e \space \a \p \p \r \o \v \e \d \space \i \n \space \2 \0 \1 \1 \space \f \o \r \space \o \u \t \p \a \t \i \e \n \t \s \space \c \o \v \e \r \e \d \space \b \y \space \p \u \b \l \i \c " ..."]]

[:content [\L \i \s \d \e \x \a \m \f \e \t \a \m \i \n \e \  \d \i \m \e \s \y \l \a \t \e \space \( \E \l \v \a \n \s \e \) \space \w \a \s \space \a \p \p \r \o \v \e \d \space \b \y \space \t \h \e \space \E \u \r \o \p \e \a \n \space \C \o \m \m \i \s \s \i \o \n \  \i \n \space \M \a \r \c \h \space \2 \0 \1 \3 \space \a \s \space \p \a \r \t \space \o \f \space \a \n \space \o \v \e \r \a \l \l \space \t \h \e \r \a \p \e \u \t \i \c \space \s \t \r \a \t \e \g \y \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t " ..."]]

Sucroferric oxyhydroxide (trade name Velphoro) has been available since August 2014 for use by adults with chronic renal failure undergoing hemodialysis or peritoneal ...

The fixed combination of the drugs dapagliflozin and metformin (Xigduo) has been approved since January 2014 for adults with type ...

[:content [\C \o \n \s \t \e \l \l \a \space \i \s \space \t \h \e \space \f \i \r \s \t \space \a \n \d \space \o \n \l \y \space \p \r \o \d \u \c \t \space \a \p \p \r \o \v \e \d \space \i \n \space \t \h \e \space \E \U \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t \space \o \f \space \I \B \S \- \C \space \i \n \space \a \d \u \l \t \s \space \a \n \d \space \h \a \s " ..."]]